 | • レポートコード：MRC2303G032 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書によると、世界の強直性脊椎炎治療市場規模が、予測期間（2023年-2028年）中、CAGR 6.4％で増加すると推測されています。本書では、強直性脊椎炎治療の世界市場について広く調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療種類別（投薬、治療、手術）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などの項目について記載しています。並びに、本書に記載されている企業情報には、Novartis AG、AbbVie Inc.、UCB、Amgen Inc.、Boehringer Ingelheim International GmbH、Celltrion Healthcare、Reliance Life Sciences、Janssen CarePathなどが含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の強直性脊椎炎治療市場規模：治療種類別 - 投薬における市場規模 - 治療における市場規模 - 手術における市場規模 ・世界の強直性脊椎炎治療市場規模：地域別 - 北米の強直性脊椎炎治療市場規模 アメリカの強直性脊椎炎治療市場規模 カナダの強直性脊椎炎治療市場規模 メキシコの強直性脊椎炎治療市場規模 … - ヨーロッパの強直性脊椎炎治療市場規模 ドイツの強直性脊椎炎治療市場規模 イギリスの強直性脊椎炎治療市場規模 フランスの強直性脊椎炎治療市場規模 … - アジア太平洋の強直性脊椎炎治療市場規模 中国の強直性脊椎炎治療市場規模 日本の強直性脊椎炎治療市場規模 インドの強直性脊椎炎治療市場規模 … - 南米/中東の強直性脊椎炎治療市場規模 ブラジルの強直性脊椎炎治療市場規模 アルゼンチンの強直性脊椎炎治療市場規模 サウジアラビアの強直性脊椎炎治療市場規模 … ・競争状況 ・市場機会・将来動向 |
The Global Ankylosing Spondylitis Market is expected to grow at a CAGR of 6.4% during the forecast period (2023 – 2028).
The COVID-19 pandemic impacted the ankylosing spondylitis market due to disruptions in various clinical studies and supply chains. Ankylosing spondylitis drug suppliers faced several challenges due to travel restrictions, business closures, stay-at-home protocols, and trade bans during the pandemic. Additionally, precautionary measures taken by governments like social distancing and restrictions have severely disrupted the patient’s treatments in the hospital. The pandemic and emergence of variants continue to cause, concern, and sudden and drastic downturn in the economic activity of several countries. This has expected to decline in the market growth during the pandemic.
The growth of the global ankylosing spondylitis drug market is majorly driven by an increase in the prevalence rate of the target disease. According to the article published by the Scandinavian Journal of Rheumatology in 2022, titled “Psoriatic arthritis, axial spondylitis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents”, the prevalence rate of spondylitis was 0.41%. Furthermore, the recent advancement in therapy, growing awareness about diagnostics and treatments for the disease, development of effective drugs are the major contributors to the growth of the market. Additionally, government initiatives and advanced healthcare infrastructure are expected to propel market growth over the forecast period.
Many companies are investing on large scale in research and development of ankylosing spondylitis drugs and therapies. Moreover, they are collaborating and adopting merger and acquisitions strategies for getting a stronger investment for the drugs. Thus, the rise in R&D investment is positively influencing the market growth. For instance, Bowie Shenqi Pill (Shanghai University of Traditional Chinese Medicine), Bimekizumab (UCB Biopharma), and Namilumab (Takeda Pharmaceuticals International GmbH) drugs are under development phase. This is expected to propel the market growth over the forecast period.
Due to a lack of awarfeness regarding ankylosing spondylitis in many nations, many individuals do not seek medical care and instead treat it as a normal ache. This scenario is particularly common in developing countries, which results in restraining the growth of the market.
Ankylosing Spondylitis Treatment Market Trends
Medication Segment is Expected to Hold a Large Share in the Market
Medication dominated the market in 2021 and is expected to grow during the forecast period due to the rise in ankylosing spondylitis patients and an increase in the adoption of medications for the treatment. Medication is focused on reducing the discomfort caused due to ankylosing spondylitis. Nonsteroidal anti-inflammatory drugs such as ibuprofen and naproxen, disease-modifying antirheumatic drugs such as methotrexate, and biologics including anti-TNF, and anti-IL7 drugs are some of the medications used to reduce pain and swelling.
Furthermore, new product launches are likely to fuel the treatment market, as they are used as the first line of treatment. For instance, in December 2021, Pfizer received approval from the United States Food and Drug Administration (FDA) for tofacitinib, known as Xeljanz or Xeljanz XR, a new medication to treat ankylosing spondylitis (AS) and other disorders like rheumatoid arthritis, juvenile Idiopathic Arthritis. Additionally, in October 2020, Cadila Pharmaceuticals launched the biosimilar of adalimumab, Cadalimab in India which is used to treat psoriatic arthritis, rheumatoid arthritis, psoriasis, and ankylosing spondylitis.
North America Dominates the Market and is Expected to do the Same Over the Forecast Period
North America is anticipated to dominate the ankylosing spondylitis treatment market due to the rise in incidences and prevalence of target diseases, the presence of key players, well-established infrastructure in the region, and the increasing adoption of the latest technologies for better diagnosis options. As per the statistics published by The National Center for Biotechnology Information, in 2021, the prevalence of ankylosing spondylitis is approximately 5% to 6% in people who are HLA-B27 positive.
In addition, the approvals of drugs in the region for the treatment of ankylosing spondylitis are further boosting the growth of the market. for instance, In Feb 2020, Taltz (ixekizumab) received approval from Health Canada for treating adults with ankylosing spondylitis who failed to respond to other treatments. Furthermore, rapid adoption of new therapies and treatment options, raising awareness, and high healthcare expenditure in the region are expected to boost the market share of the region in the industry.
Ankylosing Spondylitis Treatment Market Competitor Analysis
The global ankylosing spondylitis treatment market is moderately competitive with several players across the globe. The majority of the key player is involved in the research and manufacturing of ankylosing spondylitis therapy drugs. These market players have gained a high market share and offer a wide range of products with an extensive distribution system across the world. Some of the major key players are Novartis, Amgen, Boehringer Ingelheim International GmbH, UCB Biopharma, and AbbVie.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Target Diseases
4.2.2 Development and Commercialization of effective Product
4.3 Market Restraints
4.3.1 Huge cost of treatment
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value-USD million)
5.1 By Treatment Types
5.1.1 Medication
5.1.1.1 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.1.1.2 TNF Inhibitors
5.1.1.3 IL-17 Inhibitors
5.1.1.4 Others
5.1.2 Therapy
5.1.3 Surgery
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Novartis AG
6.1.2 AbbVie Inc.
6.1.3 UCB
6.1.4 Amgen Inc.
6.1.5 Boehringer Ingelheim International GmbH
6.1.6 Celltrion Healthcare
6.1.7 Reliance Life Sciences
6.1.8 Janssen CarePath
6.1.9 Sandoz International GmbH
6.1.10 Pfizer
7 MARKET OPPORTUNITIES AND FUTURE TRENDS